Since metastases of HNSCC are associated with poor survival of patients with HNSCC, understanding signaling pathways associated with metastases such as the mutant p53-AMPK-FOXO3a-FOXM1 pathway will offer us the opportunity to develop therapeutic strategies for HNSCC patients. This evidence concerns the gene TP53 and head and neck squamous cell carcinoma.